SANGAMO THERAPEUTICS, INC (SGMOQ)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 60M 120M 180M Q3 '16: 2.8M Q4 '16: 8.9M Q1 '17: 3.4M Q2 '17: 8.3M Q3 '17: 11.8M Q4 '17: 13.1M Q1 '18: 12.6M Q2 '18: 21.4M Q3 '18: 23.6M Q4 '18: 26.8M Q4 '18: 26.8M Q1 '19: 8.1M Q2 '19: 17.5M Q3 '19: 22M Q4 '19: 54.9M Q1 '20: 13.1M Q2 '20: 21.6M Q3 '20: 57.8M Q4 '20: 25.8M Q1 '21: 26.3M Q2 '21: 27.9M Q3 '21: 28.6M Q4 '21: 28M Q1 '22: 28.2M Q2 '22: 29.4M Q3 '22: 26.5M Q4 '22: 27.2M Q1 '23: 158M Q2 '23: 6.8M Q3 '23: 9.4M Q4 '23: 2M Q1 '24: 481K Q2 '24: 356K Q3 '24: 49.4M Q4 '24: 7.6M Q1 '25: 6.4M Q2 '25: 18.3M Q3 '25: 581K Q4 '25: 14.2M Q1 '26: 1.4M Q3 '17 Q4 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24 Q1 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q2 '16: -26.8M Q3 '16: -19.2M Q4 '16: -9.8M Q1 '17: -16.8M Q2 '17: -12.8M Q3 '17: -13M Q4 '17: -13.8M Q1 '18: -21M Q2 '18: -19.1M Q3 '18: -16.2M Q4 '18: -20.8M Q1 '19: -43.9M Q2 '19: -33.5M Q3 '19: -29.2M Q4 '19: 1.5M Q1 '20: -44.5M Q2 '20: -37.9M Q3 '20: -3.7M Q4 '20: -43.4M Q1 '21: -46.3M Q2 '21: -48.7M Q3 '21: -48.4M Q4 '21: -39.9M Q1 '22: -45.3M Q2 '22: -45.7M Q3 '22: -54.9M Q4 '22: -55.4M Q1 '23: 18M Q2 '23: -123.6M Q3 '23: -106.4M Q4 '23: -62.1M Q1 '24: -51.5M Q2 '24: -37.1M Q3 '24: 10.6M Q4 '24: -26M Q1 '25: -29.6M Q2 '25: -17.9M Q3 '25: -35.6M Q4 '25: -38.2M Q1 '26: -31.9M Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24 Q1 '26

Net Income Quarterly

-120M -80M -40M 0 40M 80M 120M Q3 '16: -19M Q4 '16: -9.6M Q1 '17: -16.6M Q2 '17: -12.5M Q3 '17: -12.4M Q4 '17: -13.1M Q1 '18: -20.2M Q2 '18: -16.6M Q3 '18: -12.8M Q4 '18: -18.7M Q4 '18: -18.7M Q1 '19: -42.1M Q2 '19: -30.3M Q3 '19: -27.3M Q4 '19: 4.6M Q1 '20: -42.9M Q2 '20: -35.9M Q3 '20: -1.6M Q4 '20: -40.6M Q1 '21: -45.9M Q2 '21: -47.2M Q3 '21: -47.7M Q4 '21: -37.5M Q1 '22: -44M Q2 '22: -43.2M Q3 '22: -53.2M Q4 '22: -52M Q1 '23: 21.1M Q2 '23: -114.5M Q3 '23: -104.2M Q4 '23: -60.3M Q1 '24: -49.1M Q2 '24: -36.1M Q3 '24: 10.7M Q4 '24: -23.4M Q1 '25: -30.6M Q2 '25: -20M Q3 '25: -34.9M Q4 '25: -37.4M Q1 '26: -31M Q3 '17 Q4 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24 Q1 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-120M -60M 0 60M 120M 180M Q2 '16: -16.2M Q3 '16: -17.6M Q4 '16: -11.8M Q1 '17: -13.1M Q2 '17: 56.8M Q3 '17: -15.7M Q4 '17: -16.8M Q1 '18: -18.1M Q2 '18: 122.4M Q3 '18: -27.6M Q4 '18: -40.2M Q1 '19: -45.1M Q2 '19: -39.6M Q3 '19: -38.9M Q4 '19: -20.8M Q1 '20: -18.9M Q2 '20: 160M Q3 '20: 33.1M Q4 '20: -4.3M Q1 '21: -68.5M Q2 '21: -52.6M Q3 '21: -59.4M Q4 '21: -52.7M Q1 '22: -59M Q2 '22: -54M Q3 '22: -53.6M Q4 '22: -57M Q1 '23: -66.3M Q2 '23: -60.7M Q3 '23: -47.3M Q4 '23: -50.5M Q1 '24: -48.7M Q2 '24: -26.9M Q3 '24: 11.8M Q4 '24: -3.4M Q1 '25: -26.1M Q2 '25: -18.2M Q3 '25: -28.5M Q4 '25: -24.4M Q1 '26: -19.3M Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24 Q1 '26

Free Cash Flow Quarterly

-120M -60M 0 60M 120M 180M Q2 '16: -16.3M Q3 '16: -17.7M Q4 '16: -12M Q1 '17: -13.5M Q2 '17: 55.1M Q3 '17: -16.4M Q4 '17: -17.7M Q1 '18: -20.8M Q2 '18: 119.3M Q3 '18: -36.9M Q4 '18: -68.2M Q1 '19: -51.1M Q2 '19: -43.4M Q3 '19: -43M Q4 '19: -27.6M Q1 '20: -22.7M Q2 '20: 157.1M Q3 '20: 29.1M Q4 '20: -8.3M Q1 '21: -76.5M Q2 '21: -59.8M Q3 '21: -64.6M Q4 '21: -55.6M Q1 '22: -61.8M Q2 '22: -59.4M Q3 '22: -58M Q4 '22: -64.5M Q1 '23: -76.5M Q2 '23: -66.3M Q3 '23: -50M Q4 '23: -53.2M Q1 '24: -48.7M Q2 '24: -26.9M Q3 '24: 11.6M Q4 '24: -3.5M Q1 '25: -26.1M Q2 '25: -18.2M Q3 '25: -28.6M Q4 '25: -24.4M Q1 '26: -19.3M Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24 Q1 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q2 '20: 139M Q3 '20: 141.1M Q1 '21: 143.1M Q2 '21: 144M Q3 '21: 145.4M Q1 '22: 146.2M Q2 '22: 148.2M Q3 '22: 158M Q1 '23: 169.2M Q2 '23: 174.3M Q3 '23: 177.2M Q1 '24: 180.3M Q2 '24: 203.9M Q3 '24: 214.3M Q1 '25: 220.3M Q2 '25: 256.9M Q3 '25: 304.3M Q1 '26: 389.6M Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q1 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.10 -1.40 -0.70 0.00 0.70 1.40 2.10 Q4 '15: -0.58 Q1 '16: -0.73 Q2 '16: -0.94 Q3 '16: -1.08 Q4 '16: -1.02 Q1 '17: -1.02 Q2 '17: -0.81 Q3 '17: -0.69 Q4 '17: -0.70 Q1 '18: -0.70 Q2 '18: -0.70 Q3 '18: -0.68 Q4 '18: -0.71 Q3 '19: -1.09 Q4 '19: -0.87 Q1 '20: -0.83 Q2 '20: -0.83 Q3 '20: -0.60 Q4 '20: -0.93 Q1 '21: -0.88 Q2 '21: -0.95 Q3 '21: -1.27 Q4 '21: -1.23 Q1 '22: -1.21 Q2 '22: -1.17 Q3 '22: -1.18 Q4 '22: -1.25 Q1 '23: -0.83 Q2 '23: -1.20 Q3 '23: -1.45 Q4 '23: -1.47 Q1 '24: -1.86 Q2 '24: -1.38 Q3 '24: -0.75 Q4 '24: -0.53 Q1 '25: -0.40 Q2 '25: -0.30 Q3 '25: -0.45 Q4 '25: -0.44 Q1 '26: -0.38 Q4 '16 Q1 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.